Camilla Heiniö

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3558565/publications.pdf

Version: 2024-02-01

| | | 1163117 | 1372567 |
|----------|----------------|--------------|----------------|
| 11 | 225 | 8 | 10 |
| papers | citations | h-index | g-index |
| | | | |
| | | | |
| | | | |
| 11 | 11 | 11 | 192 |
| all docs | docs citations | times ranked | citing authors |
| | | | |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity., 2020, 8, e000188. | | 45 |
| 2 | Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy - Oncolytics, 2020, 17, 47-60. | 4.4 | 35 |
| 3 | TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. Cells, 2020, 9, 798. | 4.1 | 26 |
| 4 | Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncolmmunology, 2020, 9, 1761229. | 4.6 | 22 |
| 5 | Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression. Oncolmmunology, 2022, 11 , . | 4.6 | 20 |
| 6 | Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. Cells, 2021, 10, 978. | 4.1 | 16 |
| 7 | Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Frontiers in Immunology, 2022, 13, 794251. | 4.8 | 16 |
| 8 | Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. Cancer Gene Therapy, 2021, 28, 442-454. | 4.6 | 15 |
| 9 | Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. Oncolmmunology, 2022, 11, 2028960. | 4.6 | 14 |
| 10 | Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology, 2021, 12, 706517. | 4.8 | 13 |
| 11 | Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. Human Gene Therapy, 2019, 30, 740-752. | 2.7 | 3 |